Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Company Overview

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Key Stats

• Today's Range: $28.47 to $30.86
• 50-Day Range: $22.88 to $30.58
• 52-Week Range: $12.59 to $47.65
• Volume: 826,708 shs
• Average Volume: 1.13 million shs
• Market Capitalization: $2.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.14
• Consensus Rating: Moderate Buy

Mineralys Therapeutics Stock Analysis - MarketRank™

Mineralys Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 149th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Mineralys Therapeutics has a consensus price target of $49.14, representing about 67.8% upside from its current price of $29.28.

Amount of Analyst Coverage

Mineralys Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mineralys Therapeutics are expected to grow in the coming year, from ($2.23) to ($1.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mineralys Therapeutics is -12.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mineralys Therapeutics is -12.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mineralys Therapeutics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.30% of the float of Mineralys Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mineralys Therapeutics has a short interest ratio ("days to cover") of 6.51.

Change versus previous month

Short interest in Mineralys Therapeutics has recently increased by 4.88%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mineralys Therapeutics does not currently pay a dividend.

Dividend Growth

Mineralys Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.83

News Sentiment

Mineralys Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Mineralys Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $3,017,855.00 in company stock, which represents 0.1250% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Mineralys Therapeutics insiders have bought 69.59% more of their company's stock than they have sold. Specifically, they have bought $7,354,269.00 in company stock and sold $4,336,414.00 in company stock.

Percentage Held by Insiders

18.94% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MLYS Stock Analysis - Frequently Asked Questions

How have MLYS shares performed this year?

Mineralys Therapeutics' stock was trading at $36.29 on January 1st, 2026. Since then, MLYS shares have decreased by 19.3% and is now trading at $29.28.

How were Mineralys Therapeutics' earnings last quarter?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) issued its quarterly earnings results on Thursday, March, 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17.
Read the conference call transcript.

When did Mineralys Therapeutics IPO?

Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Wednesday, February 8th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share.

Who are Mineralys Therapeutics' major shareholders?

Mineralys Therapeutics' top institutional investors include Pictet Asset Management Holding SA (1.25%), Candriam S.C.A. (0.97%), SG Americas Securities LLC (0.27%) and Y Intercept Hong Kong Ltd (0.16%). Insiders that own company stock include Brian Taylor Slingsby, Ra Capital Management, LP, Samsara Biocapital Gp, Llc, Jon Congleton, Srinivas Akkaraju, David Malcom Rodman, Adam Scott Levy, Daphne Karydas and Alexander M Gold.
View institutional ownership trends.

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mineralys Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MLYS
• CIK: 1933414
• Web: www.mineralystx.com
• Phone: 888-378-6240
• Fax: N/A
• Employees: 28
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Mineralys Therapeutics: $49.14
• High Price Target: $56.00
• Low Price Target: $30.00
• Potential Upside/Downside: +67.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$154.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.94%
• Return on Assets: -31.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 43.76
• Quick Ratio: 43.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.17 per share
• Price / Book: 3.58

Miscellaneous

• Outstanding Shares: 82,450,000
• Free Float: 66,836,000
• Market Cap: $2.41 billion
• Optionable: Optionable
• Beta: 0.49